Review Article

Molecular Insights into the Potential of Extracellular Vesicles Released from Mesenchymal Stem Cells and Other Cells in the Therapy of Hematologic Malignancies

Suliman A. Alsagaby

Department of Medical Laboratories Sciences, College of Applied Medical Sciences, Majmaah University, Majmaah 11932, PO Box 1712, Saudi Arabia

Correspondence should be addressed to Suliman A. Alsagaby; s.alsaqaby@mu.edu.sa

Received 17 November 2020; Revised 10 January 2021; Accepted 29 January 2021; Published 18 February 2021

Academic Editor: Islam M. Saadeldin

Copyright © 2021 Suliman A. Alsagaby. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Hematologic cancer encompasses the heterogeneous group of neoplasms that affect different stages of blood cell lineages. Despite the significant improvements made in the new modalities of anticancer therapy, many forms of blood cancer remain untreatable, putting the afflicted patients at high risk of death. Therefore, there has been an urgent need for novel therapy to improve the clinical outcomes of patients with blood cancer. Mesenchymal stem cell-derived extracellular vesicles (MSC-EVs) have been reported to possess an anticancer activity. This review discusses (i) the therapeutic potential of MSC-EVs against blood cancer, (ii) the possibility of using EVs from sources other than MSCs as a mean for blood cancer vaccination and drug delivery, and (iii) areas to be optimized for MSC-EV-based clinical application on blood malignancies.

1. Introduction

Blood cancer comprises a wide range of tumors that originate from multiple stages of myeloid or lymphoid lineages [1]. Common forms of blood neoplasms include acute myeloid leukemia (AML), chronic myeloid leukemia (CML), acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), multiple myeloma (MM), and lymphoma [2]. Chromosomal abnormalities and gene mutations have been heavily implicated in the pathogenesis and prognosis of hematologic malignancies [3–6]. For instance, the fusion of breakpoint cluster region-tyrosine-protein kinase with tyrosine-protein kinase ABL (BCR-ABL) seen in t (9; 22) is a driving mutation and characteristic of CML [7]. The deletion of cellular tumor antigen p53 (TP53) [del (17p)] underpins chemotherapy resistance in CLL [8]. The overexpression of cyclin D1 in t (11; 14) was shown to drive the growth of MM and mental cell lymphoma [9]. Similarly, the overproduction of apoptosis regulator Bcl-2 (BCL2) as a result of t (14; 18) is a hallmark and a driving mutation of follicular lymphoma [10]. Collectively, chromosomal alterations and gene mutations play a major role in the initiation and progression of blood neoplasms.

Although cancer is an age-associated disease, blood cancer is seen in adults as well as in children [11]. According to the Surveillance, Epidemiology, and End Results (SEER) Program, 137,770 new cases of leukemia and lymphoma are estimated to be recorded in the USA by the end of 2020. Despite the advances made in cancer therapy, many forms of blood cancer remain incurable [12–15]. Furthermore, chemotherapy, which is still the front-line treatment for many blood neoplasms, causes serious side effects, and drug resistance is inevitable in some cases. The five-year overall survival (5-year OS) of patients with blood cancer remains unsatisfactory; according to SEER, the 5-year OS of patients with leukemia and lymphoma was 63% and 72%, respectively. Therefore, there has been a great need for new modalities of anticancer therapy to improve the clinical outcomes of patients diagnosed with hematologic neoplasms. Interestingly, extracellular vesicles (EVs) released from mesenchymal stem cells (MSCs) have emerged as a promising mean for therapy of various diseases, such as cancer, kidney injury, liver fibrosis, traumatic brain injury, acute spinal cord injury, and myocardial infarction [16]. The present work discusses (i) the therapeutic potential of MSC-derived EVs on blood
cancer, (ii) the potential of using EVs from cells other than MSCs for blood cancer vaccination and drug delivery, and (iii) areas to be optimized for MSC-EV-based clinical application on blood malignancies.

2. Extracellular Vesicles

Extracellular vesicles (EVs) are small, bilayer, membrane-enclosed vesicles that are secreted from nearly all types of cells. EVs vary from each other by their biosynthesis, size, content, and surface markers [17]. Exosomes and microvesicles (MVs) are two common examples of EVs, with differences between them being reported on the bases of biogenesis, composition and size [18]. Exosomes are smaller than MVs with a size ranging from 40 to 100 nm in diameter and are generated by inward budding of the plasma membrane to form an early endosome that matures into late circular endosome enclosing intraluminal vesicles (ILVs). Multivesicular bodies (MVBs) describe late rounded endosomes filled with large number of MVs. MVBs fuse with the plasma membrane and release their content by exocytosis to the extracellular space. At this point, the secreted ILVs are known as exosomes (Figure 1(a)). The generation of exosomes is tightly controlled by a range of mechanisms including elements of the endosomal sorting complex required for transport (ESCRT), Rab proteins, tumor protein p53/tumor suppressor-activated pathway-6 pathway, ceramide, and neutral sphingomyelinase [19]. In contrast, MVs are bigger in size (50-1000 nm in diameter) and are created and released by outward blebbing from the plasma membrane (Figure 1(b)) [20]. Given the nature of the production of MVs, the composition of their plasma membrane shows high resemblance with that of the parent cells. Noticeably, the surface of MVs is enriched with integrins, glycoprotein Ib (GPIb), and P-selectin. The molecular content of EVs is further discussed in a later subsection. The old historical view of EVs states that they are generated and secreted from cells to eliminate cellular waste. However, further research showed that EVs are very important for cellular communications [21]. EVs circulate in different body fluids, such as blood, breast milk, and urine, in search of their target cells that they recognize via specific receptors/ligands. Once the target cells are reached, EVs exert their impact either by receptor-ligand binding of EVs with recipient cells or by delivering their content into the target cells through endocytosis, phagocytosis, pinocytosis, or membrane fusion [22]. The molecular content of EVs includes mRNAs, microRNAs, proteins, and soluble factors that alter the behavior of target cells [23]. EVs affect various biological processes—such as proliferation, apoptosis, migration, and angiogenesis—of recipient cells [24].

2.2. Mesenchymal Stem Cells and Hemopoiesis. Mesenchymal stem cells (MSCs) are nonhematopoietic cells that are characterized by (i) the surface expression of CD73, CD90, and CD105 with absence of CD19, CD14, CD34, CD45, and human leukocyte antigen-DR (HLA-DR); (ii) adhesion to plastic; and (iii) the ability to differentiate in vitro under specific conditions into different types of cells, such as adipocytes, chondrocyte, and osteocytes [32]. MSCs were reported to be isolatable from multiple sources like bone marrow, fat tissue, umbilical cord, dental pulp, placenta, and synovial fluid [33]. MSCs are indispensable components of the bone marrow (BM) microenvironment and play essential roles in hemopoiesis [33]. In the BM microenvironment, stromal cells—which consist of MSCs, adipocyte fibroblast osteoblast, and endothelial cells—are the constituents of hemopoietic niche, where hematopoietic stem cells (HSCs) reside. MSCs and other stromal cells in the hemopoietic niche provide prosurvival and stemness signals needed to protect HSCs from cell death and differentiation. As a result, HSCs are maintained alive with the ability to undergo self-renewal [34, 35]. A typical example of the crosstalk between MSCs and HSCs is the engagement of stem cell factor
SCF on MSCs with its receptor (SCFR) on HSCs to promote the maintenance and self-renewal of the latter [36]. In fact, deletion of SCF led to depletion of HSCs in a mouse model [36]. Similarly, the interaction between C-X-C motif chemokine ligand 12 (CXCL12) released from MSCs and C-X-C motif chemokine 4 receptor (CXC4R) on HSCs is necessary to maintain HSCs [37, 38]. Wnt signaling was reported to promote self-renewal and survival of HSCs [39]. Agrin, which is proteoglycan involved in the neuromuscular junction, was found to be expressed by MSCs and to induce proliferation and survival of HSCs [40]. Integrin-beta1-dependent contact between MSCs and HSCs was shown to regulate the self-renewal capacity of HSCs [41]. Taken together, normally functioning MSCs are essential for successful hemopoiesis.

2.3. Molecular Composition of MSC-EVs. The cellular origin of EVs has an impact on the molecular composition of released EVs. For instance, in addition to the known markers of exosomes (CD63, CD9, CD81, ALG-2-interacting protein X (Alix), lysosome-associated membrane glycoprotein 1 (LAMP1), and heat shock protein 7 (HSP7)), exosomes released from MSCs exhibit the typical markers of MSCs (CD29, CD73, CD90, CD105, and CD44), reflecting their cellular origin [42]. Three lipid species (diacylglycerol, sphingomyelin, and ceramides) are commonly reported in the membrane lipid of MSC-EVs [43]. Interestingly, along with the structural roles of these lipids, they have also been implicated in signal transduction, cell cycle arrest, tumor suppression, and apoptosis [44]. Applying omic approaches enabled researcher to deeply characterize the molecular content of MSC-EVs. In this context, Haraszti et al. explored the proteome and lipidome content of exosomes and MVs derived from MSCs [45]. The authors reported 972 proteins in the exosomes and 1874 proteins in the MVs. Translation, glycolysis GTPase activity, and cell motion were pathways that were significantly enriched by the common proteins in the exosomes and MVs. Extracellular matrix, binding (receptor, heparin, phospholipid, integrin) immune response, and cell adhesion were enriched by proteins specific to exosomes. In contrast, proteins that were detected only in MVs enriched mitochondria, endoplasmic reticulum, and proteasomes. These data highlight the differential composition of exosomes and MVs. The lipidomic work also reported 1961 lipid species that differed from each other by head group, number, length, and saturation of fatty acid tails. Differential lipidome was reported in the exosomes and MVs. For instance, acyl carnitines, lysophosphatidyl cholines, cholesterol esters, ceramides, and sphingomyelins showed higher concentration in MVs compared with exosomes. In contrast, free fatty acids, cardiolipins, glycolipid, and lysophosphatidyl serines exhibited increased concentration in exosomes compared with MVs. Another study explored the proteome of exosomes released from three different sources (umbilical cord (UC) MSCs, bone marrow (BM) MSCs, and adipose tissue (AT) MSCs) that reported 1014 proteins of which 37 protein, 23 proteins, and 341 proteins were specific to UC-MSC-exosomes, AT-MSC-exosomes, and BM-MSC-exosomes, respectively [46]. These data may reflect the impact of exosome source on the exosome content and perhaps function. In contrast to the exosomes of UC and AT, those released from BM highly expressed proteins that have been implicated in transcription activation, integrin-mediated signaling, monocyte activation, innate immune, hypoxia, and tubulin binding. In the context of nucleic acids, Baglio et al. compared the RNA pool in MSCs and in their exosomes and reported a striking RNA signature being associated with exosomes [47]. The most abundant class of RNA in MSCs was small nuclear RNA (snRNA) followed by miRNA. However, transfer RNA and repeat RNA dominated the exosome
content of RNA. Noticeably, the exosome composition of miRNA was small (2.5% of the total of small RNA), but was dominated (43-59% of miRNA) by five miRNAs (miR-143-3p, miR-10b-5p, miR-486-5p, miR-22-3p, and miR-21-5p) that were implicated in the regulation of cell cycle, immune response, and cell migration. This finding indicated a selective incorporation of miRNAs into exosomes perhaps to fulfill the specific function. Ferguson et al. characterized the MSC-exosome content of miRNA; the most abundant miRNAs (n = 23) were predicted to target 5481 genes with high stringency. These genes constitute pathways like Wnt signaling, profibrotic signaling via transforming growth factor beta (TGF-β) and platelet-derived growth factor (PDGF), proliferation, and apoptosis [48].

2.4. Normal MSC-EV-Based Therapy. Given the roles that normal MSCs play in hematopoiesis, it has been suggested that EVs secreted from normal MSCs may restore normal hematopoiesis in patients with blood cancer. In line with this view, in vivo findings reported by Roccaro et al. showed that tumor growth and metastasis of multiple myeloma (MM) in mice inoculated with the MM cell line (MM.1S) and exosomes released from primary MM BM-MSCs were high compared with that seen in mice administrated with BM-MSC-EVs and normal BM-MSC-EVs on the growth and exosomes derived from normal BM-MSCs [49]. A later study attempted to explain the opposite impact of MM-BM-MSC-EVs and normal BM-MCS-EVs on the growth and metastasis of MM [50]. The study showed that in contrast to MM-BM-MSC-MVs from MM patients, normal BM-MSC-MVs reduced the proliferation, migration, and survival of five MM cell lines (U266, ARP-1, MM.1S, OPM-2, and RPMI 8226). The authors attributed the differential effect of BM-MSC-MVs from MM patients and healthy donors on MM cells to the less adequacy of normal BM-MSC-EVs compared with MM BM-MSC-EVs to increase the expression and/or phosphorylation of mitogen-activated protein kinases (MAPKs: extracellular signal-regulated kinase 1/2 (ERK1/2) and c-Jun N-terminal kinase (JNK)), translation initiation (TI) factors (eukaryotic translation initiation factor 4G (eIF4GI) and eukaryotic translation initiation factor 4E (eIF4E)), TI regulator (target of rapamycin kinase (TOR)), MAP kinase-interacting serine/threonine-protein kinase 1/2 (MNK1/2) and eukaryotic translation initiation factor 4E-binding protein (4EBP)) and oncogenes (nuclear factor kappaB (NFκB), mothers against decapentaplegic homolog 5 (SMAD5), cyclin D, hypoxia-induced factor 1 alpha (HIF1α), and transcriptional effector cMyc (cMyc)). A further clarification of the distinct influence of MM BM-MSC-EVs and normal BM-MSC-EVs came from a study that characterized the content of EVs from the two sources [49]. Interestingly, the levels of oncoproteins, cytokines, and adhesion molecules were greater in MM BM-MSC-EVs compared with normal BM-MSC-EVs. In contrast to MM BM-MSC-EVs, BM-MSC-EVs from healthy donors exhibited low levels of interleukin6 (IL6), C-C motif chemokine 2 (CCL2), and fibronectin, as well as high levels of miR15a. CCL2 was previously shown to be in vitro and in vivo essential for the growth of MM [51, 52], and 15a miR was reported to inhibit the proliferation and induces apoptosis in MM cells through targeting AKT serine/threonine-protein-kinase (AKT3), ribosomal-protein-S6, MAP-kinases, and NF-κB-activator MAP3KIP3 [53]. Collectively, normal BM-MSC-EVs appeared to hold promise for MM therapy; therefore, further work is to be conducted in order to clinically employ them for the treatment of patients with MM.

In the context of the influence of donor age on the therapeutic potential of normal BM-MSC-EVs, young donor-derived BM-MSC-exosomes were found to be more competent to inhibit MM-induced angiogenesis compared with BM-MSC-exosomes from old donors [54]. The exosomal content of miRs in young and old donors was shown to possess different signatures; 24 miRs were upregulated, and 12 miRs were downregulated in BM-MSC-exosomes from young donors compared with those from old donors. Interestingly, the greater therapeutic potential of young donor-derived BM-MSC-exosomes attributed, at least partially, to the increased level of miR430 that blocks angiogenesis through the hepatocyte growth factor/hepatocyte growth factor receptor (HGF/HGFR) signaling pathway in endothelial cells [54]. The reduced capability of BM-MSC-exosomes from old people to inhibit MM-induced angiogenesis may explain the association of MM with age [55]. These data may direct the extraction of BM-MSC-exosomes to be limited to young donors as they are better than old donors in providing highly competent BM-MSC-exosomes.

Unlike BM-MSC-EVs of healthy people, BM-MSC-EVs derived from patients with myelodysplastic syndrome (MDS) appeared to play roles in the deregulation of hematopoiesis. Muntión et al. reported increased survival and clonogenicity of hematopoietic progenitor cells CD34+ postincubation with MDS BM-MSC-EVs, but not with BM-MSC-EVs from healthy donors [56]. The researchers studied the exosomal content of miRs and found higher levels of miR132, miR136, miR15a, miR10a, and miR198 in BM-MSC-exosomes from MDS patients compared with healthy donors. Interestingly, miR10a and miR15a are overexpressed in hematopoietic cells from MDS patients and were also implicated in the pathogenesis of the disease [57, 58]. Noticeably, the incorporation of MDS BM-MSC-exosomes into hematopoietic progenitors increases the levels of miR10a and miR15a in the later, hence contributing to the development of MDS. [56] In contrast, the incorporation of BM-MSC-exosomes from healthy donors did not elevate the expression of miR10a and miR15a, thus giving a possible explanation of why normal BM-MSC-exosomes did not contribute to the deregulation of hematopoiesis seen in MDS patients [52]. Taken together, normal BM-MSC-exosomes may have the potential to restore normal hemopoiesis in MDS patients.

In acute myeloid leukemia (AML), miR155 and miR375 are independent risk factors of disease recurrence [59]. Interestingly, the exosomal content of these two miRs in relation to parent BM-MSCs was shown to be greater in AML patients compared with healthy donors [60]. Furthermore, BM-MSC-exosomes from AML patients showed a higher level of epidermal growth factor (EGF) compared with those isolated from healthy donors [60]. Interestingly, the expression of epidermal growth factor receptor (EGFR) on AML cells was shown to strongly associate with poor prognosis.
of the disease, proposing a pathological involvement of EGF/EGFR signaling in AML [61]. These data suggest that unlike normal BM-MSC-exosomes, AML BM-MSC-exosomes support the growth of AML. In line with this view, BM-MSC-exosomes from AML patients, but not from healthy donors, were shown to protect AML cells from chemotherapy (fms-like tyrosine kinase 3 (FLT3) inhibitor AC220) [60]. These data rationalize a possible utility of normal BM-MSC-exosomes in the treatment of AML, especially in patients with resistance to chemotherapy.

In patients with blood malignancies, the application of allogeneic hematopoietic stem cell transplantation (allo-HSCT) has earned wide acceptance due to its curative capability [62]. Suppressed immune reactivity of allo-HSCT recipients, complete clearance of tumor cells in patients, and protection against microbial infections are important factors that increase the success rate of allo-HSCT-based therapy [63]. Low tolerance of the host immune system to allo-HSCT causes an induction of T-cell-based immune response against the transplant, which can lead to engraftment failure; this is seen in the graft versus host disease (GVHD) [64]. Patients who develop GVHD undergo immunosuppressant-based therapy using steroids. However, a substantial proportion of patients shows resistance to the treatment; so, they are considered at high risk of death due to GVHD or its complications [65].

As discussed earlier, MSCs are essential components of the hematopoiesis microenvironment; in fact, MSCs heavily contribute to normal hematopoiesis through their impact on the survival, proliferation, and differentiation of HSCs [66]. Therefore, the systemic infusion of MSCs from BM or UC has been used to improve the clinical outcomes of allo-HSCT. The favored impact of MSCs on allo-HSCT was attributed to the capacity of MSCs to modulate the immune reactivity of host and to promote allo-HSCT engraftment [67–71]. Furthermore, in steroid refractory GVHD post-allo-HSCT, BM-MSC infusion has also been shown to be a safe treatment option to alleviate the disease burden and improve patients’ survival [72–74].

In consistence with roles of MSCs in the improvement of clinical outcomes of allo-HSCT and GVHD, BM-MSC-EVs were reported to enhance the viability and to limit the differentiation of UCHSCs [75]. Noticeably, in vivo coadministration of BM-MSC-EVs with UCHSCs enhanced the migration capacity of the latter from peripheral blood to BM and supported the formation of hematopoietic niche, pointing out the desired impact of BM-MSC-EVs in the engraftment of UCHSCs [75]. Molecular findings provided explanation for these observations: UCHSCs increased the expression of 103 genes and reduced the expression of 100 genes posttreatment with BM-MSC-EVs. The upregulated genes were implicated in cell movement and cell growth, whereas the downregulated genes were involved in cell death. Interestingly, genes that promote cell migration, such as protein L1b (L1b), granulocyte-macrophage colony-stimulating factor (CSF2), C-C motif chemokine 3 (CCL3), endothelial transcription factor GATA-2 (GATA2), and CXCR4, were among the highly expressed genes in UCHSCs. The authors further studied the mechanism by which the BM-MSC-EVs exerted their influence on UCHSCs and reported increased levels of miRs in the EVs whose target genes were downregulated in UCHSCs (miR-3168/LYZ, miR-27b-3p/ZFP36, miR21-5p/ANXA1) [75]. This result indicated that the altered transcriptome of UCHSCs posttreatment with BM-MSC-EVs is driven, at least partially, by the EV content of miRs.

In vivo experiments linked the amelioration of acute GVHD by BM-MSC-exosomes, but not exosomes from normal human dermal fibroblasts (NHDFs) to the ability of the former to suppress T-helper cells and T-cytotoxic cells [76]. Furthermore, the BM-MSC-exosomes inhibited the differentiation of naïve T-cells to effector cells as evidenced by the reversed ratio of CD62L<sup>+</sup>CD44<sup>+</sup>/CD62L<sup>−</sup>CD44<sup>+</sup>. The BM-MSC-exosomes also preserved naïve regulatory T-cells (Treg); the exosomes repressed the stimulation of CD45RA<sup>+</sup>Foxp3<sup>+</sup> naïve Treg to CD45RA<sup>+</sup>Foxp3<sup>+</sup> effector Treg. The differential profile of miRs in BM-MSC-exosomes and NHDF-exosomes proposed an explanation for the immunomodulatory roles of BM-MSC-exosomes; miRs that target mRNAs implicated in cellular proliferation, T-cell receptor (TCR) signaling, and GVHD were overexpressed in BM-MSC-exosomes compared with NHDF-exosomes.

In a mouse model of allo-HSCT, human UC-MSC-EVs alleviated the burden of acute GVHD and increased the survival rate of recipient mice [77]. The underpinning mechanism appeared to be the ability of UC-MSC-EVs to elevate the ratio of Th cells/T-cytotoxic cells along with the serum level of IL10 and decrease the serum content of interleukin 2 (IL-2), tumor necrosis alpha (TNF-α), and tumor necrosis gamma (IFN-γ). In the chronic GVHD mice model, exosomes derived from BM-MSCs, but not fibroblasts, were able to lighten the symptoms of the disease [78]. The immunosuppression activity of BM-MSC-exosomes was clearly manifested in their ability to repress the activation and infiltration of CD4 T-cells in the lung tissue. BM-MSC-exosomes induced Treg and inhibited the activation and migration of pathogenic T-cells (Th17) [78], which have been heavily implicated in the pathogenesis of chronic GVHD [79]. In vivo experiments also showed reduced production of Th17 proinflammatory cytokines—such as interleukin 17A (IL-17A), interleukin 21 (IL-21), interleukin 22 (IL-22), and IL-2, caused by MSC-exosomes [78].

Kordelas et al. examined the curative potential of BM-MSC-exosomes in patients with steroid-resistant acute GVHD following allo-HSCT and reported a significant decrease of the disease burden [80]. Interestingly, the authors found increased levels of anti-inflammatory molecules—such as IL10, transforming growth factor beta (TGF-beta) and human leukocyte antigen G (HLAG) in the BM-MSC-exosomes that coincided with the reduced levels of proinflammatory cytokines, including IL6, IL17a, IL21, TNF-α, and IFN-γ and proapoptosis protein–like soluble FAS ligand. Consistently, a significant decrease in the production of proinflammatory cytokines from patients’ BPMCs was found postadministration with BM-MSC-exosomes. Noticeably, the immunosuppression capability of the BM-MSC-exosomes varied significantly between the donors. Of the
four donors, one had higher levels of IL10 and TGF beta and lower levels of IFN-γ. These findings highlight three points: (i) BM-MSC-exosomes are clinically applicable for the treatment of allo-HSCT-induced steroid-resistant acute GVHD, (ii) the desired effect of BM-MSC-exosomes on GVHD was attributed to the ability of the exosomes to suppress the immunoreaction of host towards the graft, and (iii) evaluating the immunosuppression potential of BM-MSC-exosomes extracted from multiple donors is justified to select the most potent source for clinical application.

3. Exosome-Based Vaccine

The content of EVs is derived from their cellular source; hence, EVs cargo can be used to indicate their cellular origin. This finding gave a rationale for using cancer exosomes to direct the immune system to fight cancer cells. The concept of exosome-based vaccine evolves around the idea that cancer-derived exosomes harboring tumor-specific protein is internalized by dendritic cells (DCs) and processed to be presented on their surface in order to activate naïve T-cells [81]. This in turn initiates an immune response specific to tumor cells. Following the same concept, Shen et al. reported that the incorporation of exosomes secreted from acute myeloid leukemia (AML) cells into pulsed dendritic cells (DC) induced cytotoxic T-lymphocytes (CTLs) immunity against AML cells, which killed the leukemic cells [82]. The same notion was applied on chronic myeloid leukemia (CML), where CML-exosomes were incorporated into DCs that initiated CTL-based immunity against CML cells [83]. Similar findings were reported using an in vivo setting; mice administrated with DCs containing CML-exosomes were immune-protected against the development of CML postadministration with CML cells [83]. Interestingly, manipulation of the content of tumor-derived exosomes was shown to support the efficacy of exosome-based cancer vaccine. In an in vivo setting, the forced increased expression of IL2, by transfection, in tumor exosomes showed better immunogenicity against lymphoma cells compared with nontransfected tumor exosomes [84]. Similar findings were observed using tumor exosomes manipulated to overexpress IL18 [85]. Given the roles of transforming growth factor-β1 (TGF-β1) in immunosuppression, it is employed by tumor cells for immunoevasive strategies [86]. Therefore, silenced TGF-β1 leukemic exosomes were shown in vivo to be more potent than leukemic exosomes expressing TGF-β1 to trigger CTL-based immunity against lymphocytic leukemia [87]. Overall, these data demonstrated a promising potential of exosome-based vaccine in tackling hematologic neoplasms. However, further work is needed to investigate the clinical utility of an exosome-based vaccine.

3.1. Targeting EVs. Given the supportive impact of EVs released from the tumor microenvironment, including BM-MSCs, on the growth, survival, and metastasis of blood malignancies, targeting such EVs seems justified for tumor therapy. The protumor role of these EVs was proposed to be targetable by blocking their biogenesis, release, or uptake. Koch et al. blocked exosome biogenesis using indomethacin and reported increased sensitivity of lymphoma cells to chemotherapy [88]. Javidi-Sharifi et al. also reported that inhibition or silencing of fibroblast growth factor receptor (FGFR) blocked the secretion of exosomes, which in turn abolished the protective impact of the tumor microenvironment on leukemia cells [89]. Similarly, inhibition of exosomes release by dimethyl amiloride (DMA) was found to sensitize lymphoma cells (EL4 cell line) to chemotherapy in mice [90]. Depletion of exosomes seems to be an attractive strategy to increase chemotherapy efficacy [91]. MM-derived exosomes were shown to be incorporated into BM-MSCs, promoting their survival and proliferation [92]. Using inhibitor (heparin) that interferes with endocytosis pathways reduced the uptake of MM-exosomes by BM-MSCs, which antagonized the positive impact of the former on the later [92]. Targeting exosome shedding from AML stem cells by increasing the expression of miR-34-5p showed antitumor activity against AML cells in vitro and in vivo [93]. Exosomes secreted from B-cell lymphoma were shown to carry CD20, which was found to consume the anti-CD20 monoclonal antibody rituximab used for the disease therapy. In vitro removal of exosomes increased the cytolytic activity of rituximab against lymphoma cells [94]. It is important to mention that unselective targeting of EVs is a double-edged sword, because it does not distinguish between “pathological” EVs, the targeting of which is beneficial, and the “physiological” EVs, which are necessary for normal cellular communication. Therefore, development of selective means by which EVs with protumor activity can be targeted is essential to provide a novel method for blood cancer therapy.

3.2. EVs for Drug Delivery. The small size of EVs enables them to cross the blood-brain barrier; the high similarity between the EV membrane and cellular membrane makes the former immune-tolerable, and the architecture of EV’s protects their cargo from the degradation action by nucleases and proteases [95, 96]. These three features have made EVs an attractive mean for drug delivery. The concept of using EVs as therapeutic delivery system evolves around the idea that therapeutic molecule—such as miR, protein, or chemotherapy—can be endogenously or exogenously enclosed in EVs and applied in vitro or in vivo to be delivered to the target tissue [97]. Parent cells can be loaded or forced to overexpress an antitumor molecule, resulting in high loading of such molecules in the biosynthesized EVs, which can be isolated following their secretion from the parent cells (endogenous loading) [98]. For the exogenous loading, EVs are first isolated and then loaded with anticancer molecules using various methods, such as electroporation [98]. CML blasts are known to highly express interleukin 3 receptor (IL3R) on their surface compared with normal hematopoietic stem cells; therefore, IL3R may serve as a biomarker to specifically target CML blasts [99, 100]. BCR-ABL is a fused protein with a persistent tyrosine kinase activity that underpins the growth of CML [101]. Bellavia et al. engineered exosomes to endogenously overexpress a fragment of IL3 on their surface and to be loaded with imatinib (tyrosine kinase inhibitor) or BCR-ABL siRNA [102]. The application of the engineered exosomes selectively inhibited the growth of
| Category               | Source of EVs                      | Type of EVs | Disease | Experimental settings                                                                 | Findings                                                                                                           | Ref |
|------------------------|-----------------------------------|-------------|---------|----------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------|-----|
| Normal MSC-EV-based therapy | BM-MSCs from healthy donors and MM patients | Exosomes   | MM      | Mice were administrated with MM cells (MM.1S cell line) and exosomes from normal BM-MSCs or MM BM-MCSs. Next, differences in the exosomes content from the two sources were sought. | Unlike MM BM-MCS-exosomes, normal BM-MSC-exosomes inhibited the growth and metastasis of MM cells in mice. Normal BM-MSC-exosomes had low levels of IL6, CCL2, and fibronectin and high levels of 15a miR compared with MM BM-MSC-exosomes. Normal BM-MSC-MVs inhibited the growth, survival, and migration of MM cells. In contrast to MVs from MM BM-MSCs, these from normal BM-MSC limited expression and/or phosphorylation of MAPKs (ERK1/2 and JNK), translation initiation (TI) factors (eIF4GI and eIF4E), TI regulator (TOR, MNK1/2 and 4EBP), and oncogenes (NFκB, SMAD5, cyclin D, HIF1α, cMyc) in MM cells. MM-induced angiogenesis was strongly inhibited by BM-MSC-exosomes from young donors compared with that from old donors. Increased survival and clonogenicity of hematopoietic progenitor were observed postincubation with BM-MSC-EVs from MDS patients but not healthy donors. Unlike MDS BM-MSC-EVs, these from healthy donors did not increase the expression of miR10a and miR 15a, which are implicated in the development of MDS, in the hematopoietic progenitor. In contrast to exosomes from AML patients, exosomes of healthy donors sensitized AML cells to chemotherapy (FLT3 inhibitor). In vitro, BM-MSC-EVs supported the viability and restricted the differentiation of UCHSCs. Postincubation, UCHSCs increased the expression of genes involved in cell movement and growth and reduced expression of genes implicated in apoptosis. The EVs enclosed miRs whose target genes in UCHSCs were reduced implying a mechanism of action. Coadministration of UCHSCs with BM-MSC-EVs in mice augmented the engraftment of UCHSCs. | [49] [50] [54] [56] |
| Normal MSC-EV-based therapy | BM-MSCs from healthy donors and MM patients | MVs        | MM      |Normal or MM BM-MSC-MVs were in vitro incubated with MM cells (cell lines: U266, ARPI, MM1S, OPM2, and RPMI 8226). Next, the crosstalk between the MVs and MM cells was studied. | BM-MSC-EVs were in vitro incubated with hematopoietic progenitor cells CD341. | [50] |
| Normal MSC-EV-based therapy | BM-MSCs from healthy donors and MDS patients | EVs        | MDS     | BM-MSC-EVs were in vitro incubated with hematopoietic progenitor cells CD341. | BM-MSC-exosomes were in vitro incubated with AML cells. | [56] |
| Normal MSC-EV-based therapy | BM-MSCs from healthy donors and AML patients | Exosomes   | AML     |BM-MSC-exosomes were in vitro incubated with AML cells. | BM-MSC-EVs were in vitro incubated with UCHSCs. Next, the transcriptome of UCHSCs was characterized postincubation. The BM-MSC-EV content of miRs was also sequenced. In mice, UCHSCs with or without BM-MSC-EVs were injected. | [75] |
| Normal MSC-EV-based therapy | BM-MSCs from healthy donors | Exosomes   | Allo-HSCT-induced GVHD | BM-MSC-EVs were in vitro incubated with UCHSCs. Next, the transcriptome of UCHSCs was characterized postincubation. The BM-MSC-EV content of miRs was also sequenced. In mice, UCHSCs with or without BM-MSC-EVs were injected. | BM-MSC-exosomes were found to carry reduced levels of proinflammatory and anti-inflammatory cytokines were | [80] |
| Normal MSC-EV-based therapy | BM-MSCs from healthy donors | Exosomes   | Allo-HSCT-induced GVHD | BM-MSC-exosomes were found to carry reduced levels of proinflammatory and anti-inflammatory cytokines were | BM-MSC-exosomes were found to carry reduced levels of proinflammatory and anti-inflammatory cytokines were | [80] |
Table 1: Continued.

| Category | Source of EVs | Type of EVs | Disease | Experimental settings | Findings | Ref |
|----------|---------------|-------------|---------|------------------------|----------|-----|
| based therapy | induced acute GVHD | measured in BM-MSC-exosomes derived from four donors. The most potent source was selected for administration into patient with steroid-resistant acute GVHD postallo-HSCT. Proinflammatory cytokines of the patient's PBMCs were measured following administration of BM-MSC-exosomes. | proinflammatory cytokines (IL6, IL17a, IL21, TNF-a, IFN-g) and high levels of anti-inflammatory molecules (IL10, TGF beta, and HLAG). The immunomodulatory potential of the BM-MSC-exosomes differed significantly between the donors. The administration of BM-MSC-exosomes into the patient reduced the production of proinflammatory cytokines from PBMCs and improved the symptoms of GVHD. Only exosomes from BM-MSCs were able to ameliorate the symptoms of GVHD. BM-MSC-exosomes suppressed T-helper cells and T-cytotoxic cells. In contrast to exosomes from NHDFs, these from BM-MSCs enclosed higher levels of miRs that target genes implicated in cellular proliferation, TCR signaling and GVHD. | [76] |
| Normal MSC-EVs-based therapy | BM-MSCs and NHDFs from healthy donors | Exosomes | Acute GVHD | Exosomes from BM-MSCs and NHDFs were administrated into mice with acute GVHD. Next, cellular immune response was studied. Exosomal content of miRs was also characterized. | UC-MSC-EVs alleviated the burden of acute GVHD and increased the survival rate of recipient mice. The serum levels of IL-2, TNF-α, and IFN-γ dropped postinjection with UC-MSC-EVs. In contrast, the level of IL10 in serum and the ration of Th-cells/T-cytotoxic cells were increased. Improvement of GVHD symptoms was possible only postinjection with BM-MSC-exosomes. The activation, migration, and infiltration of CD4 T-cells were inhibited by BM-MSC-exosomes but not fibroblast-exosomes. BM-MSC-exosomes also reduced the production of proinflammatory cytokines (IL-17A, IL-21, IL-22, and IL-2) in PBMCs of mice. | [77] |
| Normal MSC-EVs-based therapy | UC-MSC from healthy donors | EVs | Allo-HSCT-induced acute GVHD | UC-MSC-EVs were injected into a mouse model of allo-HSCT with acute GVHD. Next, the immune response in mice was studied. | | |
| Normal MSC-EVs-based therapy | BM-MSCs and fibroblasts from healthy donors | Exosomes | Chronic GVHD | Exosomes from BM-MSCs or fibroblasts were inoculated into mice with chronic GVHD. Next, the immune response in mice was studied. | | [78] |
| Exosome-based vaccine | AML cells (NP4 cell line) | Exosomes | AML | AML cell exosomes were in vitro incorporated into pulsed dendritic cells (DC). The DCs were then incubated with T-lymphocytes (CTLs). Next, CTLs as effector cells were in vitro incubated with AML cells. | CTLs became immunized against AML cells postincubation with DCs, in which AML cell exosomes were internalized. CTLs confer cytotoxicity against AML cells. DCs incorporating CML cell-exosome-induced immunity of CTLs that caused death of CML cells in vitro. The administration of the DCs to mice protected them from developing CML postinoculation with CML cells. | [82] |
| Exosome-based vaccine | CML cells (K562 cell line) | Exosomes | CML | In vitro pulsed DCs uptook CML cell exosomes. CTLs were incubated with the DCs. Next, CML cells were treated with the CTLs in vitro and in vivo. | | [83] |
| Category                  | Source of EVs | Type of EVs | Disease | Experimental settings                                                                 | Findings                                                                 | Ref |
|---------------------------|---------------|-------------|---------|----------------------------------------------------------------------------------------|---------------------------------------------------------------------------|-----|
| Exosome-based vaccine     | LL cells (L1210 cell line) | Exosomes | LL      | Exosomes from LL cells that lack or express TGF-β1 were independently internalized by DCs. Next, DCs were injected into mice. The mice were then inoculated with LL cells. FGFR was inhibited (or gene silenced) in BM-MSCs (HS-5 cell line). Next, the BM-MSCs were in vitro incubated with AML and CML (MOLM14 and K562 cell lines). The leukemic cells were also administrated to Fgf2 -/- and Fgf2 +/+ mice. | The DCs incorporated with exosomes lacking the expression of TGF-β1 conferred stronger protection against LL compared with DCs that uptook TGF-β1 expressing exosomes. Targeting FGFR inhibited the release of exosomes from BM-MSC, which abolished the protective impact of the BM-MSCs on the leukemia cells. Mice lacking the expression of FGF2 survived longer than those that that expressed FGF2. | [87] [89] |
| Targeting EVs             | BM-MSCs (HS-5 cell line) | EVs        | AML and CML | Mice were injected with lymphoma cells (EL4 cell line). Then, they were treated with cyclophosphamide with or without DMA. | DMA inhibited exosomes release in vivo. Furthermore, the combination of cyclophosphamide with DMA significantly reduced the tumor growth, while cyclophosphamide alone had a little effect on the tumor growth. In the absence of heparin, MM cell exosomes were internalized by BM-MSCs, which reprogrammed the latter to support the MM growth. Heparin inhibited the uptake of MM cell exosomes by BM-MScs; hence, the tumor-supportive impact of BM-MSCs was abolished. | [90] [92] |
| Targeting EVs             | Lymphoma cells (EL4 cell line) | Exosomes | Lymphoma | Exosomes from MM cell lines (RPMI8226, H929, MM1S and U266) with or without endocytosis inhibitor (heparin) were incubated with BM-MSCs. | AML stem cells were transfected with miR-34c-5p mimic, and the proliferation of AML cells was assayed. Mice were transplanted with AML cells. Three weeks later, the mice were treated with miR-34c-5p agomir. In vitro, the increased expression miR-34c- blocked the release of exosomes from AML stem cells. In vivo miR-34c-p-dependent blockage of exosomes shedding antagonized the growth of AML in mice. | [93] |
| Targeting EVs             | MM cell lines (RPMI8226, H929, MM1S and U266) | Exosomes | MM      | Exosomes from MM cell lines (RPMI8226, H929, MM1S and U266) with or without endocytosis inhibitor (heparin) were incubated with BM-MSCs. | AML stem cells were transfected with miR-34c-5p mimic, and the proliferation of AML cells was assayed. Mice were transplanted with AML cells. Three weeks later, the mice were treated with miR-34c-5p agomir. In vitro, the increased expression miR-34c- blocked the release of exosomes from AML stem cells. In vivo miR-34c-p-dependent blockage of exosomes shedding antagonized the growth of AML in mice. | [93] |
| Targeting EVs             | AML stem cells | Exosomes | AML     | Exosomes from MM cell lines (RPMI8226, H929, MM1S and U266) with or without endocytosis inhibitor (heparin) were incubated with BM-MSCs. | AML stem cells were transfected with miR-34c-5p mimic, and the proliferation of AML cells was assayed. Mice were transplanted with AML cells. Three weeks later, the mice were treated with miR-34c-5p agomir. | [93] |
| Targeting EVs             | B-cell lymphoma primary cells and cell lines (Su-DHL-4, Balm-3, OCI-Ly1). | Exosomes | B-cell lymphoma | B-cell lymphoma cells express high level of surface CD20, which bound to rituximab, protecting the malignant cells from the cytolytic effect of the drug. Inhibition of exosomes release form B-cell lymphoma cells sensitized them to rituximab. | HEK293T cell were forced to express surface IL3 and were treated with a kinase inhibitor (Imatinib) or BCR-ABL siRNA. Next, Exosomes with the surface expression of IL3 that contained imatinib or BCR-ABL siRNA were isolated and then treated with rituximab. The engineered exosomes selectively inhibited the growth of CML in vitro and in vivo. The distribution analysis of the engineered exosomes in vivo showed that they accumulated at the tumor site. | [94] [102] |
| EVs for drug delivery     | Embryonic kidney cells (HEK293T cell line) | Exosomes | CML     | Exosomes from LL cells that lack or express TGF-β1 were independently internalized by DCs. Next, DCs were injected into mice. The mice were then inoculated with LL cells. FGFR was inhibited (or gene silenced) in BM-MSCs (HS-5 cell line). Next, the BM-MSCs were in vitro incubated with AML and CML (MOLM14 and K562 cell lines). The leukemic cells were also administrated to Fgf2 -/- and Fgf2 +/+ mice. | The DCs incorporated with exosomes lacking the expression of TGF-β1 conferred stronger protection against LL compared with DCs that uptook TGF-β1 expressing exosomes. Targeting FGFR inhibited the release of exosomes from BM-MSC, which abolished the protective impact of the BM-MSCs on the leukemia cells. Mice lacking the expression of FGF2 survived longer than those that that expressed FGF2. DMA inhibited exosomes release in vivo. Furthermore, the combination of cyclophosphamide with DMA significantly reduced the tumor growth, while cyclophosphamide alone had a little effect on the tumor growth. In the absence of heparin, MM cell exosomes were internalized by BM-MSCs, which reprogrammed the latter to support the MM growth. Heparin inhibited the uptake of MM cell exosomes by BM-MScs; hence, the tumor-supportive impact of BM-MSCs was abolished. | [87] [89] [90] [92] [93] [94] [102] |
**Table 1: Continued.**

| Category | Source of EVs | Type of EVs | Disease | Experimental settings | Findings | Ref |
|----------|---------------|-------------|---------|-----------------------|----------|-----|
| EVs for drug delivery | Embryonic kidney cells (HEK293T-cell line) | Exosomes | CML | applied to imatinib-resistant CML blast (LAMA84 and K562 cell lines) in vitro. The engineered exosomes were also injected into mice that were previously inoculated with CML blasts. | The exosomes were taken by the CML blast, and miR-21 sponge-MS2 was delivered, leading to apoptosis induction in the malignant cells. Aptamer AS1411 enhanced the ability of the exosomes to target CML blasts. | [103] |
| EVs for drug delivery | Embryonic kidney cells (HEK293T-cell line) | Exosomes | CML | Exosomes released from HEK293T cells were isolated, alkalinized, and exogenously loaded with miR328. The exosomes were for the treatment of imatinib-resistant CML blasts (K562 cell line). Exosomes from NIH3T3 cells were either endogenously or exogenously loaded with siRNA of c-myc. Next, lymphoma cells with an overexpression of c-myc were treated with the exosomes. | The endocytosis of the exosomes into imatinib-resistant CML blasts sensitized the later to imatinib. | [106] |
| EVs for drug delivery | Fibroblasts (NIH3T3 cell line) | Exosomes | Lymphoma | The exosomes were loaded with siRNA of c-myc, which is an oncogene that is implicated in the pathogenesis of various kinds of cancer, was found to inhibit tumor growth | The delivery of the exosomes into lymphoma cells reduced the expression of c-myc and inhibited the growth of lymphoma. | [107] |

CML blasts in vitro and in vivo [102]. The overexpressed fragment of IL3 on the exosomes facilitated the selective targeting of CML blasts that also overproduced IL3R. Another similar example was reported by Huang et al, where exosomes were endogenously loaded with inhibitors of miR21 and were modified to carry aptamer AS1411 on their surface [103]. It was reported that miR21 plays important roles in the pathogenesis of different types of malignancies, including hematological cancer [104]. Nucleolin, which exhibit high affinity to aptamer AS1411, is highly expressed on the surface of blood cancer cells, making it a possible marker that could be utilized for targeted therapy [105]. Using the aforementioned exosomes, Huang et al. reported enhanced endocytosis of the exosomes into CML blast due to the surface aptamer AS1411 as well as apoptosis induction in the leukemic cells as a result of delivery of miR21 inhibitors [103]. Decreasing the expression of miR328 was reported to be essential for imatinib resistance in leukemia cells [106]. Interestingly, the same study reported that alkalized exosomes enclosing exogenous miR328 restored imatinib sensitivity of the leukemic cells. In lymphoma cells, the endocytosis of exosomes carrying siRNA of c-myc, which is an oncogene that is implicated in the pathogenesis of various kinds of cancer, was found to inhibit tumor growth [107].

3.3. Areas for Improvement. In the past decade, a large number of studies investigated the potential of EVs, secreted from MSCs or other types of cells, in the treatment of blood cancer. Collectively, these studies demonstrated promising roles for the EVs in the therapy of hematologic neoplasms, allo-HSCT, and/or allo-HSCT-induced GVHD (summary is shown in Table 1). Despite the strikingly encouraging findings reported on the therapeutic potential of MSC-EVs, it is early for MSC-EVs to be considered off-shelf treatment for patients with blood neoplasms. In fact, several issues need to be addressed prior to the clinical application of MSC-EVs. For instance, the process of selecting a source of MSCs is still not clear; EVs from BM-MSCs have been more commonly studied compared with EVs from UC-MSCs in the context of the treatment of blood cancer. Therefore, additional investigations are required to compare the therapeutic potential of EVs from the two sources and provide guidelines for choosing the most potent source of MSC-EVs. Another important issue is the selection of suitable donor; age-matched donor-derived MSC-EVs exhibit variable immunomodulatory impact on allo-HSCT-induced GVHD [80]. Therefore, developing a standardize protocol for assessing the therapeutic potency of MSC-EVs prior to clinical application is essential to achieve desired treatment outcomes. Interestingly, MSC-EVs from younger donors appeared to have greater anticancer activity compared with those isolated from.
older healthy subjects [54]. Further work is needed to determine the optimum donor age that gives the most potent MSC-EVs.

Another critical point is the isolation procedure of MSC-EVs; researchers have been applying different protocols to extract MSC-EVs [108]. Commonly, ultracentrifugation has been utilized for the isolation of EVs. However, this technique is time-consuming, laborious, and prone to cosedimentation of macromolecules with EVs, reducing the purity of EVs [109]. Ultracentrifugation also has low EV recovery, and the ultra-gravity forces may disrupt the integrity of EVs. Collectively, these drawbacks of ultracentrifugation-based isolation may negatively impact the functionality of isolated EVs [109]. On the other hand, ultrafiltration followed by size exclusion chromatography (UF-SEC) was shown to reward higher EV yield with greater purity [110]. Furthermore, UF-SEC preserved the EV content of protein and other biomolecules, which positively impact the functionality of EVs [110]. Work is still ongoing to produce a golden standard method for EV isolation with optimal recovery, purity, and preserved integrity.

EVs encompass MVs and exosomes that display functional differences, due to the variation in their molecular content [111]. Development of a robust protocol that distinguishes between MVs and exosomes (as some population of MVs overlaps in size with exosomes) is needed in order to attribute the therapeutic potential to either MVs or exosomes, but not EVs. Durcin et al. reported protein and lipid signatures that differentiate between EVs with different sizes [112]. Such knowledge can be employed to create a standardized method based on affinity-dependent capture that isolates highly pure MVs or exosomes.

In vitro expansion of MSCs is dependent on cell culture format and condition. For example, the three-dimensional (3D) cell culture is more potent than the 2D cell culture in mimicking the physiological condition. Therefore, the 3D cell culture-based expansion of MSCs was shown to better preserve their physiological properties and enhance their therapeutic potential [113]. Similarly, cell culture cytokines and growth factors have been shown to potentize the therapeutic impact of MSC-EVs [114]. Therefore, procedure for in vitro amplification and pretreatment of MSCs remains to be standardized.

Other areas that have not been fully explored and standardized for the clinical use of MSC-EVs include potency criteria and storage of MSC-EVS [16]. There is a need for developing biomarkers that recognize the most potent and stable MSC-EVs within molecularly heterogeneous populations of MSC-EVs. Such biomarkers (especially surface proteins) can be then utilized to affinity-based isolate the best MSCs-EV for clinical application and long-term storage.

4. Conclusion

A great amount of research has been conducted in the past decade to study the biogenesis, composition, biological function, and therapeutic potential of MSC-EVs. These studies have provided valuable insights into the capability of MSC-EVs to exert antitumor and immunomodulatory effects. Therefore, MSC-EVs have been proposed as a promising option of therapy in patients (i) having hematological tumors, (ii) undergoing allo-HSCT, and/or (iii) developing GVHD postallo-HSCT. Despite the strikingly encouraging findings of the EVs, their clinical application remained hampered by the lack of sufficient preclinical studies and standardized protocols. Therefore, the future work should be directed to these two areas in order to clinically harness the MSC-EVs for the treatment of blood cancer.

Data Availability

No data availability statement was included in the manuscript.

Conflicts of Interest

The author declares that there is no conflict of interest.

Acknowledgments

The author would like to thank the Deanship of Scientific Research at Majmaah University in Saudi Arabia for supporting this work under Project Number [R-2021-28]. Figure 1 was created using BioRender application (https://biorender.com/).

References

[1] R. J. Buchsbaum and R. S. Schwartz, “Cellular origins of hematologic neoplasms,” The New England Journal of Medicine, vol. 322, no. 10, pp. 694–696, 1990.
[2] J. Taylor, W. Xiao, and O. Abdel-Wahab, “Diagnosis and classification of hematologic malignancies on the basis of genetics,” Blood, vol. 130, no. 4, pp. 410–423, 2017.
[3] S. A. Alsagaby, P. Brennan, and C. Pepper, “Key molecular drivers of chronic lymphocytic leukemia,” Clinical Lymphoma Myeloma and Leukemia, vol. 16, no. 11, pp. 593–606, 2016.
[4] S. A. Alsagaby, “Omics-based insights into therapy failure of pediatric B-lineage acute lymphoblastic leukemia,” Oncology Reviews, vol. 13, no. 2, 2019.
[5] D. Russo, J. V. Garcia-Gutierrez, S. Soverini, and M. Baccarani, “Chronic myeloid leukemia prognosis and therapy: criticisms and perspectives,” Journal of Clinical Medicine, vol. 9, no. 6, p. 1709, 2020.
[6] D. Grimwade and R. K. Hills, “Independent prognostic factors for AML outcome,” Hematology, vol. 2009, no. 1, pp. 385–395, 2009.
[7] R. Ren, “Mechanisms of BCR-ABL in the pathogenesis of chronic myelogenous leukaemia,” Nature Reviews Cancer, vol. 5, no. 3, pp. 172–183, 2005.
[8] E. Campo, F. Cymbalist, P. Ghia et al., “TP53aberrations in chronic lymphocytic leukemia: an overview of the clinical implications of improved diagnostics,” Haematologica, vol. 103, no. 12, pp. 1956–1968, 2018.
[9] P. L. Bergsagel and W. M. Kuehl, “Critical roles for immunoglobulin translocations and cyclin D dysregulation in multiple myeloma,” Immunological Reviews, vol. 194, no. 1, pp. 96–104, 2003.
[10] C. Correia, P. A. Schneider, H. Dai et al., “BCL2 mutations are associated with increased risk of transformation and shortened survival in follicular lymphoma,” Blood, vol. 125, no. 4, pp. 658–667, 2015.

[11] D. Rodriguez-Abreu, A. Bordoni, and E. Zucca, “Epidemiology of hematological malignancies,” Annals of Oncology, vol. 18, pp. 15–18, 2007.

[12] N. J. Short, M. Konopleva, T. M. Kadia et al., “Advances in the treatment of acute myeloid leukemia: new drugs and new challenges,” Cancer Discovery, vol. 10, no. 4, pp. 506–525, 2020.

[13] A. A. Lettner, A. Hochhaus, and M. C. Muller, “Current treatment concepts of CML,” Current Cancer Drug Targets, vol. 11, no. 1, pp. 31–43, 2011.

[14] B. Eichhorst, M. Hallek, and V. Goede, “New treatment approaches in CLL: challenges and opportunities in the elderly,” Journal of Geriatric Oncology, vol. 7, no. 5, pp. 375–382, 2016.

[15] S. Giri and N. C. Munshi, “Challenges in multiple myeloma diagnosis and treatment,” Leukemia Supplements, vol. 2, Supplement 1, pp. S1–S9, 2013.

[16] O. P. B. Wiklander, M. Á. Brennan, J. Lötvall, X. O. Breakefield, and S. el Andaloussi, “Advances in therapeutic applications of extracellular vesicles,” Science Translational Medicine, vol. 11, no. 492, p. eaav8521, 2019.

[17] E. Cocucci and J. Meldolesi, “Ectosomes and exosomes: shedding the confusion between extracellular vesicles,” Trends in Cell Biology, vol. 25, no. 6, pp. 364–372, 2015.

[18] G. Raposo and W. Stoorvogel, “Extracellular vesicles: exosomes, microvesicles, and friends,” The Journal of Cell Biology, vol. 200, no. 4, pp. 373–383, 2013.

[19] L. de Luca, S. Trino, I. Laurenzana et al., “Mesenchymal stem cell derived extracellular vesicles: a role in hematopoietic transplantation?,” International Journal of Molecular Sciences, vol. 18, no. 5, p. 1022, 2017.

[20] J. C. Akers, D. Gonda, R. Kim, B. S. Carter, and C. C. Chen, “Biogenesis of extracellular vesicles (EV): exosomes, microvesicles, retrovirus-like vesicles, and apoptotic bodies,” Journal of Neuro-Oncology, vol. 113, no. 1, pp. 1–11, 2013.

[21] L. Cruz, J. A. A. Romero, R. P. Iglesia, and M. H. Lopes, “Extracellular vesicles: decoding a new language for cellular communication in early embryonic development,” Frontiers in Cell and Developmental Biology, vol. 6, p. 94, 2018.

[22] G. Lou, Z. Chen, M. Zheng, and Y. Liu, “Mesenchymal stem cell derived exosomes as a new therapeutic strategy for liver diseases,” Experimental & Molecular Medicine, vol. 49, no. 6, article e346, 2017.

[23] E. Boillard, “Thematic review series: exosomes and microvesicles: lipids as key components of their biogenesis and functions extracellular vesicles and their content in bioactive lipid mediators: more than a sack of microRNA,” Journal of Lipid Research, vol. 59, no. 11, pp. 2037–2046, 2018.

[24] G. Van Niel, G. d’Angelo, and G. Raposo, “Shedding light on the cell biology of extracellular vesicles,” Nature Reviews Molecular Cell Biology, vol. 19, no. 4, pp. 213–228, 2018.

[25] M. Y. Konoshenko, E. A. Lekhnov, A. V. Vlassov, and P. P. Laktionov, “Isolation of extracellular vesicles: general methodologies and latest trends,” BioMed Research International, vol. 2018, Article ID 8545347, 27 pages, 2018.

[26] C. Théry, S. Amigorena, G. Raposo, and A. Clayton, “Isolation and characterization of exosomes from cell culture supernatants and biological fluids,” Current Protocols in Cell Biology, vol. 30, no. 1, pp. 3–22, 2006.

[27] F. Momen-Heravi, L. Balaji, S. Alian et al., “Current methods for the isolation of extracellular vesicles,” Biological Chemistry, vol. 394, no. 10, pp. 1253–1262, 2013.

[28] D. W. Greening, R. Xu, H. Ji, B. J. Tauro, and R. J. Simpson, A Protocol for Eososome Isolation and Characterization: Evaluation of Ultracentrifugation, Density-Gradient Separation, and Immunoaffinity Capture Methods, Springer, 2015.

[29] M. L. Alvarez, M. Khosroheidari, R. Kanchi Ravi, and J. K. DiStefano, “Comparison of protein, microRNA, and mRNA yields using different methods of urinary exosome isolation for the discovery of kidney disease biomarkers,” Kidney International, vol. 82, no. 9, pp. 1024–1032, 2012.

[30] D. D. Taylor and S. Shah, “Methods of isolating extracellular vesicles impact down-stream analyses of their cargoes,” Methods, vol. 87, pp. 3–10, 2015.

[31] K. W. Witwer, E. I. Buzás, L. T. Bems et al., “Standardization of sample collection, isolation and analysis methods in extracellular vesicle research,” Journal of Extracellular Vesicles, vol. 2, no. 1, article 20360, 2013.

[32] M. Dominici, K. le Blanc, I. Mueller et al., “Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement,” Cytotherapy, vol. 8, no. 4, pp. 315–317, 2006.

[33] P. Bianco, P. G. Robey, and P. J. Simmons, “Mesenchymal stem cells: revisiting history, concepts, and assays,” Cell Stem Cell, vol. 2, no. 4, pp. 313–319, 2008.

[34] M. F. Pittenger, A. M. Mackay, S. C. Beck et al., “Multilineage potential of adult human mesenchymal stem cells,” Science, vol. 284, no. 5411, pp. 143–147, 1999.

[35] E. M. Horwitz, K. le Blanc, M. Dominici et al., “Clarification of the nomenclature for MSC: the International Society for Cellular Therapy position statement,” Cytotherapy, vol. 7, no. 5, pp. 393–395, 2005.

[36] L. Ding, T. L. Saunders, G. Enikolopov, and S. J. Morrison, “Endothelial and perivascular cells maintain haematopoietic stem cells,” Nature, vol. 481, no. 7382, pp. 457–462, 2012.

[37] L. Ding and S. J. Morrison, “Haematopoietic stem cells and early lymphoid progenitors occupy distinct bone marrow niches,” Nature, vol. 495, no. 7440, pp. 231–235, 2013.

[38] A. Greenbaum, Y. M.-S. Hsu, R. B. Day et al., “CXCL12 in early mesenchymal progenitors is required for haematopoietic stem cell maintenance,” Nature, vol. 495, no. 7440, pp. 227–230, 2013.

[39] M. C. Florian, K. J. Nattamai, K. Dörr et al., “A canonical to non-canonical Wnt signalling switch in haematopoietic stem cell ageing,” Nature, vol. 503, no. 7476, pp. 392–396, 2013.

[40] C. Mazzon, A. Anselmo, J. Cibella et al., “The critical role of agrin in the hematopoietic stem cell niche,” Blood, vol. 118, no. 10, pp. 2733–2742, 2011.

[41] S. Gottschling, R. Saffrich, A. Seckinger et al., “Human mesenchymal stromal cells regulate initial self-renewing divisions of hematopoietic progenitor cells by a β1-integrin-dependent mechanism,” Stem Cells, vol. 25, no. 3, pp. 798–806, 2007.

[42] R. S. Lindoso, F. Collino, and A. Vieyra, “Extracellular vesicles as regulators of tumor fate: crosstalk among cancer stem cells, tumor cells and mesenchymal stem cells,” Stem Cell Investigation, vol. 4, no. 9, p. 75, 2017.
[43] K. C. Vallabhaneni, P. Penfornis, S. Dhule et al., “Extracellular vesicles from bone marrow mesenchymal stem/stromal cells transport tumor regulatory microRNA, proteins, and metabolites,” Oncotarget, vol. 6, no. 7, pp. 4953–4967, 2015.

[44] S. A. F. Morad and M. C. Cabot, “Ceramide-orchestrated signalling in cancer cells,” Nature Reviews Cancer, vol. 13, no. 1, pp. 51–65, 2013.

[45] R. A. Haraszti, M.-C. Didiot, E. Sapp et al., “High-resolution proteomic and lipidomic analysis of exosomes and microvesicles from different cell sources,” Journal of Extracellular Vesicles, vol. 5, no. 1, p. 32570, 2016.

[46] Z.-G. Wang, Z. Y. He, S. Liang, Q. Yang, P. Cheng, and A. M. Chen, “Comprehensive proteomic analysis of exosomes derived from human bone marrow, adipose tissue, and umbilical cord mesenchymal stem cells,” Stem Cell Research & Therapy, vol. 11, no. 1, p. 511, 2020.

[47] S. R. Baglio, K. Rooijers, D. Koppers-Lalic et al., “Human bone marrow-adipose-mesenchymal stem cells secrete exosomes enriched in distinctive miRNA and tRNA species,” Stem Cell Research & Therapy, vol. 6, no. 1, p. 127, 2015.

[48] S. W. Ferguson, J. Wang, C. J. Lee et al., “The microRNA regulatory landscape of MSC-derived exosomes: a systems view,” Scientific Reports, vol. 8, no. 1, p. 1419, 2018.

[49] A. M. Rocco, A. Sacco, P. Maiso et al., “BM mesenchymal stromal cell–derived exosomes facilitate multiple myeloma progression,” The Journal of Clinical Investigation, vol. 123, no. 4, pp. 1542–1555, 2013.

[50] M. Dabahb, O. Attar-Schneider, S. Tartakover Matalon et al., “Microvesicles derived from normal and multiple myeloma bone marrow mesenchymal stem cells differentially modulate myeloma cells’ phenotype and translation initiation,” Carcinogenesis, vol. 38, no. 7, pp. 708–716, 2017.

[51] K. Jöhrer, K. Janke, J. Krugmann, M. Fiegl, and R. Greil, “Transendothelial migration of myeloma cells is increased by tumor necrosis factor (TNF)-α via TNF receptor 2 and autocrine up-regulation of MCP-1,” Clinical Cancer Research, vol. 10, no. 6, pp. 1901–1910, 2004.

[52] B. K. Arendt, A. Velazquez-Dones, R. C. Tschumper et al., “Interleukin 6 induces monocye chemoattractant protein-1 expression in myeloma cells,” Leukemia, vol. 16, no. 10, pp. 2142–2147, 2002.

[53] A. M. Rocco, A. Sacco, B. Thompson et al., “MicroRNAs 15a and 16 regulate tumor proliferation in multiple myeloma,” Blood, vol. 113, no. 26, pp. 6669–6680, 2009.

[54] T. Umezu, S. Imanishi, K. Azuma et al., “Replenishing exosomes from older bone marrow stromal cells with miR-340 inhibits myeloma-related angiogenesis,” Blood Advances, vol. 1, no. 13, pp. 812–823, 2017.

[55] D. D. Alexander, P. J. Mink, H. O. Adami et al., “Multiple myeloma: a review of the epidemiologic literature,” International Journal of Cancer, vol. 120, no. S12, pp. 40–61, 2007.

[56] S. Muntión, T. L. Ramos, M. Diez-Campelo et al., “Microvesicles from mesenchymal stromal cells are involved in HPC-microenvironment crosstalk in myelodysplastic patients,” PLoS One, vol. 11, no. 2, article e0146722, 2016.

[57] X. Li, F. Xu, C. Chang et al., “Transcriptional regulation of miR-10a/b by TWIST-1 in myelodysplastic syndromes,” Haematologica, vol. 98, no. 3, pp. 414–419, 2013.

[58] A. Pons, B. Nomdeau, A. Navarro et al., “Hematopoiesis-related microRNA expression in myelodysplastic syndromes,” Leukemia & Lymphoma, vol. 50, no. 11, pp. 1854–1859, 2009.

[59] G. Marcucci, K. S. Maharry, K. H. Metzeler et al., “Clinical role of microRNAs in cytogenetically normal acute myeloid leukemia: miR-155 upregulation independently identifies high-risk patients,” Journal of Clinical Oncology, vol. 31, no. 17, pp. 2086–2093, 2013.

[60] S. Viola, E. Traer, J. Huan et al., “Alterations in acute myeloid leukemia bone marrow stromal cell exosome content coincide with gains in tyrosine kinase inhibitor resistance,” British Journal of Haematology, vol. 172, no. 6, pp. 983–986, 2016.

[61] J. Z. Sun, Y. Lu, Y. Xu et al., “Epidermal growth factor receptor expression in acute myelogenous leukemia is associated with clinical prognosis,” Hematological Oncology, vol. 30, no. 2, pp. 89–97, 2012.

[62] B. Gyurkocz, A. Rezvani, and R. F. Storb, “Allogeneic hematopoietic cell transplantation: the state of the art,” Expert Review of Hematology, vol. 3, no. 3, pp. 285–299, 2010.

[63] M. G. Roncarolo, S. Gregori, B. Lucarelli, F. Ciceri, and R. Bacchetta, “Clinical tolerance in allogeneic hematopoietic stem cell transplantation,” Immunological Reviews, vol. 241, no. 1, pp. 145–163, 2011.

[64] M. F. Zahid and D. A. Rizzieri, “Haploidentical hematopoietic stem cell transplantation: expanding the horizon for hematologic disorders,” Advances in Hematology, vol. 2016, Article ID 1423493, 8 pages, 2016.

[65] H. Narimatsu, “Immune reactions following cord blood transplantations in adults,” Stem Cells International, vol. 2011, Article ID 607569, 6 pages, 2011.

[66] C. Pontikoglou, F. Deschaseaux, L. Sensebé, and H. A. Papadaki, “Bone marrow mesenchymal stem cells: biological properties and their role in hematopoiesis and hematopoietic stem cell transplantation,” Stem Cell Reviews and Reports, vol. 7, no. 3, pp. 569–589, 2011.

[67] M. E. Bernardo and W. E. Fibbe, “Mesenchymal stromal cells and hematopoietic stem cell transplantation,” Immunology Letters, vol. 168, no. 2, pp. 215–221, 2015.

[68] H. M. Lazarus, O. N. Koc, S. M. Devine et al., “Cotransplantation of HLA-identical sibling culture-expanded mesenchymal stem cells and hematopoietic stem cells in hematologic malignancy patients,” Biology of Blood and Marrow Transplantation, vol. 11, no. 5, pp. 389–398, 2005.

[69] R. Friedman, M. Betancur, L. Boissel, H. Tuncer, C. Cetrulo, and H. Klingemann, “Umblilical cord mesenchymal stem cells: adjuvants for human cell transplantation,” Biological Blood and Marrow Transplantation, vol. 13, no. 12, pp. 1477–1486, 2007.

[70] Y. Wu, Y. Cao, X. Li et al., “Cotransplantation of haploidentical hematopoietic and umbilical cord mesenchymal stem cells for severe aplastic anemia: successful engraftment and mild GvHD,” Stem Cell Research, vol. 12, no. 1, pp. 132–138, 2014.

[71] N. Meuleman, T. Tondreau, I. Ahmad et al., “Infusion of mesenchymal stromal cells can aid hematopoietic recovery following allogeneic hematopoietic stem cell myeloablative transplant: a pilot study,” Stem Cells and Development, vol. 18, no. 9, pp. 1247–1252, 2009.

[72] F. Baron, M. Labopin, A. Ruggeri et al., “Unrelated cord blood transplantation for adult patients with acute myeloid leukemia: higher incidence of acute graft-versus-host disease and lower survival in male patients transplanted with female donors,” Leukemia & Lymphoma, vol. 50, no. 11, pp. 1854–1859, 2009.
unrelated cord blood—a report from Eurocord, the Acute Leukemia Working Party, and the cord blood Committee of the Cellular Therapy and Immunobiology Working Party of the European Group for Blood and Marrow Transplantation,” *Journal of Hematology & Oncology*, vol. 8, no. 1, p. 107, 2015.

[73] O. Ringdén, M. Uzunel, I. Rasmusson et al., “Mesenchymal stem cells for treatment of therapy-resistant graft-versus-host disease,” *Transplantation*, vol. 81, no. 10, pp. 1390–1397, 2006.

[74] I. Müller, S. Kordowich, C. Holzwarth et al., “Application of multipotent mesenchymal stromal cells in pediatric patients following allogeneic stem cell transplantation,” *Blood Cells, Molecules & Diseases*, vol. 40, no. 1, pp. 25–32, 2008.

[75] L. de Luca, S. Trino, I. Laurenzana et al., “MiRNAs and piRNAs from bone marrow mesenchymal stem cell extracellular vesicles induce cell survival and inhibit cell differentiation of cord blood hematopoietic stem cells: a new insight in transplantation,” *Oncotarget*, vol. 7, no. 6, pp. 6676–6692, 2016.

[76] S. Fujii, Y. Miura, A. Fufishiro et al., “Graft-versus-host disease amelioration by human bone marrow mesenchymal stromal/stem cell-derived extracellular vesicles is associated with peripheral preservation of Naïve T cell populations,” *Stem Cells*, vol. 36, no. 3, pp. 434–445, 2018.

[77] L. Wang, Z. Gu, X. Zhao et al., “Extracellular vesicles released from human umbilical cord-derived mesenchymal stromal cells prevent life-threatening acute graft-versus-host disease in a mouse model of allogeneic hematopoietic stem cell transplantation,” *Stem Cells and Development*, vol. 25, no. 24, pp. 1874–1883, 2016.

[78] P. Lai, X. Chen, L. Guo et al., “A potent immunomodulatory role of exosomes derived from mesenchymal stromal cells in preventing cGVHD,” *Journal of Hematology & Oncology*, vol. 11, no. 1, p. 135, 2018.

[79] L. W. Kappel, G. L. Goldberg, C. G. King et al., “IL-17 contributes to CD4-mediated graft-versus-host disease,” *Blood*, vol. 113, no. 4, pp. 945–952, 2009.

[80] L. Kordelas, V. Rehmann, A. K. Ludwig et al., “MSC-derived exosomes: a novel tool to treat therapy-refractory graft-versus-host disease,” *Leukemia*, vol. 28, no. 4, pp. 970–973, 2014.

[81] B. Zhang, Y. Yin, R. C. Lai, and S. K. Lim, “Immunotherapeutic potential of extracellular vesicles,” *Frontiers in Immunology*, vol. 5, p. 518, 2014.

[82] C. Shen, S. G. Hao, C. X. Zhao, J. Zhu, and C. Wang, “Antileukemia immunity: effect of exosomes against NB4 acute promyelocytic leukemia cells,” *The Journal of International Medical Research*, vol. 39, no. 3, pp. 740–747, 2011.

[83] Y. Yao, C. Wang, W. Wei et al., “Dendritic cells pulsed with leukemia cell-derived exosomes more efficiently induce anti-leukemic immunities,” *PloS One*, vol. 9, no. 3, article e91463, 2014.

[84] Y. Yang, F. Xiu, Z. Cai et al., “Increased induction of antitumor response by exosomes derived from interleukin-2 gene-modified tumor cells,” *Journal of Cancer Research and Clinical Oncology*, vol. 133, no. 6, pp. 389–399, 2007.

[85] S. Dai, X. Zhou, B. Wang et al., “Enhanced induction of dendritic cell maturation and HLA-A* 0201-restricted CEAspecific CD8+ CTL response by exosomes derived from IL-18 gene-modified CEA-positive tumor cells,” *Journal of Molecular Medicine*, vol. 84, no. 12, pp. 1067–1076, 2006.

[86] S. Nakamura, T. Yaguchi, N. Kawamura et al., “TGF-β1 in tumor microenvironments induces immunosuppression in the tumors and sentinel lymph nodes and promotes tumor progression,” *Journal of Immunotherapy*, vol. 37, no. 2, pp. 63–72, 2014.

[87] F. Huang, J. Wan, S. Hao, X. Deng, L. Chen, and L. Ma, “TGF-β1-silenced leukemia cell-derived exosomes target dendritic cells to induce potent anti-leukemic immunity in a mouse model,” *Cancer Immunology, Immunotherapy*, vol. 66, no. 10, pp. 1321–1331, 2017.

[88] R. Koch, T. Aung, D. Vogel et al., “Nuclear trapping through inhibition of exosomal export by indomethacin increases cytostatic efficacy of doxorubicin and paxitron,” *Clinical Cancer Research*, vol. 22, no. 2, pp. 395–404, 2016.

[89] N. Javidi-Sharifi, J. Martinez, I. English et al., “FGF2-FGFR1 signaling regulates release of leukemia-protective exosomes from bone marrow stromal cells,” *eLife*, vol. 8, article e40033, 2019.

[90] F. Chalmin, S. Ladoire, G. Mignot et al., “Membrane-associated Hsp72 from tumor-derived exosomes mediates STAT3-dependent immunosuppressive function of mouse and human myeloid-derived suppressor cells,” *The Journal of Clinical Investigation*, vol. 120, no. 2, pp. 457–471, 2010.

[91] A. M. Marleau, C. S. Chen, J. A. Joyce, and R. H. Tullis, “Exosome removal as a therapeutic adjuvant in cancer,” *Journal of Translational Medicine*, vol. 10, no. 1, p. 134, 2012.

[92] Y. Zheng, C. Tu, J. Zhang, and J. Wang, “Inhibition of multiple myeloma-derived exosomes uptake suppresses the functional response in bone marrow stromal cell,” *International Journal of Oncology*, vol. 54, no. 3, pp. 1061–1070, 2019.

[93] D. Deng, H. Wang, L. Li et al., “miR-34c-5p promotes eradication of acute myeloid leukemia stem cells by inducing senescence through selective RAB27B targeting to inhibit exosome shedding,” *Leukemia*, vol. 32, no. 5, pp. 1180–1188, 2018.

[94] T. Aung, B. Chapuy, D. Vogel et al., “Exosomal evasion of humoral immunotherapy in aggressive B-cell lymphoma modulated by ATP-binding cassette transporter A3,” *Proceedings of the National Academy of Sciences of the United States of America*, vol. 108, no. 37, pp. 15336–15341, 2011.

[95] D. Rufino-Ramos, P. R. Albuquerque, V. Carmona, R. Perfeito, R. J. Nobre, and L. Pereira de Almeida, “Extracellular vesicles: novel promising delivery systems for therapy of brain diseases,” *Journal of Controlled Release*, vol. 262, pp. 247–258, 2017.

[96] K. E. Gilligan and R. M. Dwyer, “Extracellular vesicles for cancer therapy: impact of host immune response,” *Cell*, vol. 9, no. 1, p. 224, 2020.

[97] S.-I. Ohno, G. Drummen, and M. Kuroda, “Focus on extracellular vesicles: development of extracellular vesicle-based therapeutic systems,” *International Journal of Molecular Sciences*, vol. 17, no. 2, p. 172, 2016.

[98] S. el Andaloussi, I. Mäger, X. O. Breakefield, and M. J. A. Wood, “Extracellular vesicles: biology and emerging therapeutic opportunities,” *Nature Reviews Drug Discovery*, vol. 12, no. 5, pp. 347–357, 2013.

[99] E. Nievergall, H. S. Ramshaw, A. S. M. Yong et al., “Monoclonal antibody targeting of IL-3 receptor α with CSL362 effectively depletes CML progenitor and stem cells,” *Blood*, vol. 123, no. 8, pp. 1218–1228, 2014.
U. Testa, R. Riccioni, S. Militi et al., “Elevated expression of IL-3Ra in acute myelogenous leukemia is associated with enhanced blast proliferation, increased cellularity, and poor prognosis,” *Blood*, vol. 100, no. 8, pp. 2980–2988, 2002.

X. An, A. K. Tiwari, Y. Sun, P. R. Ding, C. R. Ashby Jr., and Z. S. Chen, “BCR-ABL tyrosine kinase inhibitors in the treatment of Philadelphia chromosome positive chronic myeloid leukemia: a review,” *Leukemia Research*, vol. 34, no. 10, pp. 1255–1268, 2010.

D. Bellavia, S. Raimondo, G. Calabrese et al., “Interleukin 3-receptor targeted exosomes inhibit in vitro and in vivo Chronic Myelogenous leukemia cell growth,” *Theranostics.*, vol. 7, no. 5, pp. 1333–1345, 2017.

L. Huang, N. Gu, X. E. Zhang, and D. B. Wang, “Light-inducible exosome-based vehicle for endogenous RNA loading and delivery to leukemia cells,” *Advanced Functional Materials*, vol. 29, no. 9, p. 1807189, 2019.

R. Kumarswamy, I. Volkmann, and T. Thum, “Regulation and function of miRNA-21 in health and disease,” *RNA Biology*, vol. 8, no. 5, pp. 706–713, 2011.

Y. Otake, S. Soundararajan, T. K. Sengupta et al., “Overexpression of nucleolin in chronic lymphocytic leukemia cells induces stabilization of bcl2 mRNA,” *Blood*, vol. 109, no. 7, pp. 3069–3075, 2007.

Y. Dong, Y. Lin, X. Gao et al., “Targeted blocking of miR328 lysosomal degradation with alkalized exosomes sensitizes the chronic leukemia cells to imatinib,” *Blood*, vol. 109, no. 7, pp. 3069–3075, 2007.

T. R. Lunavat, S. C. Jang, L. Nilsson et al., “RNAi delivery by exosome-mimetic nanovesicles - Implications for targeting c-Myc in cancer,” *Biomaterials*, vol. 102, pp. 231–238, 2016.

F. Momen-Heravi, *Isolation of Extracellular Vesicles by Ultra-centrifugation*, Springer, New York, 2017.

I. Furi, F. Momen-Heravi, and G. Szabo, "Extracellular vesicle isolation: present and future," *Annals of Translational Medicine*, vol. 5, no. 12, p. 263, 2017.

J. Z. Nordin, Y. Lee, P. Vader et al., “Ultrafiltration with size-exclusion liquid chromatography for high yield isolation of extracellular vesicles preserving intact biophysical and functional properties,” *Nanomedicine: Nanotechnology, Biology and Medicine*, vol. 11, no. 4, pp. 879–883, 2015.

M. Kanada, M. H. Bachmann, J. W. Hardy et al., “Differential fates of biomolecules delivered to target cells via extracellular vesicles,” *Proceedings of the National Academy of Sciences of the United States of America*, vol. 112, no. 12, pp. E1433–E1442, 2015.

M. Durcin, A. Fleury, E. Taillebois et al., “Characterisation of adipocyte-derived extracellular vesicle subtypes identifies distinct protein and lipid signatures for large and small extracellular vesicles,” *Journal of Extracellular Vesicles*, vol. 6, no. 1, p. 1305677, 2017.

M. Madrigal, K. S. Rao, and N. H. Riordan, “A review of therapeutic effects of mesenchymal stem cell secretions and induction of secretory modification by different culture methods,” *Journal of Translational Medicine*, vol. 12, no. 1, p. 260, 2014.

M. di Trapani, G. Bassi, M. Midolo et al., “Differential and transferable modulatory effects of mesenchymal stromal cell-derived extracellular vesicles on T, B and NK cell functions,” *Scientific Reports*, vol. 6, no. 1, p. 24120, 2016.